Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Eli Lilly and Company Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity CNBC Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment statnews.com Eli Lilly Weight-Loss Drug Mounjaro …
Read More »Tag Archives: tirzepatide
Tirzepatide reduces obesity-associated breast cancer growth in mouse model
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. “Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in …
Read More »Hormone therapy supercharges tirzepatide, unleashing major weight loss after menopause
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study presented at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. “These data are the first to show the combined use of tirzepatide and menopause …
Read More »